Syndax Pharmaceuticals, Inc. Increase (Decrease) in Other Current Assets
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Other Current Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2024-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2025 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2024 was -$463.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$463.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$463.00K 10-Q · filed 2025-11-03 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |